NCCN guidelines recommend follow up for germline testing if tumour alterations, including BRCA1 and BRCA2, are detected and/or if there is a strong family history of cancer [36], and ESMO guidelines recommend that patients with pathogenic mutations in cancer‐risk genes, identified through tumour testing, should be referred for germline testing and genetic counselling [41]. Here, BRCA2 is linked to neoplasm.